Quarterly Activities and Cash Flow Report – September 2025

Key Highlights from the Quarter

• Further promising developments from the ongoing ACCENT trial of narmafotinib in metastatic pancreatic cancer were presented, including additional confirmed responses and an interim median Progression Free Survival figure of 7.6 months. This latter result is a 2-month improvement on historical data for chemotherapy alone.
• Ethics approval was obtained in Australia for the new trial of narmafotinib, investigating a combination with the chemotherapy FOLFIRINOX, and the first patients in this trial have been dosed.
• A key patent protecting narmafotinib has been allowed by the US Patent and Trademarks Office.
• Completion of a capital raise of A$27.5 million (before costs), funding the company into 2027.